Market cap
$4 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
9.9
Div. Yield
0 %
| Organovo Holdings (ONVO) | 2seventy bio (TSVT) | |
|---|---|---|
Market cap ($ Mln) |
4 | 266 |
Revenue ($ Mln) |
0 | 48 |
Net Profit ($ Mln) |
-12.39 | -4.09 |
Net Margin (%) |
-10,151.64 | -8.46 |
RoE (%) |
-352.55 | -1.85 |
Price to Earnings |
-- | -- |
Price-To-Book |
9.89 | 1.24 |
Income Statement ($ Mln)
| Organovo Holdings (ONVO) | 2seventy bio (TSVT) | |
|---|---|---|
|
Operating Revenue
|
0.11 | 37.86 |
|
Cost of Revenue
|
5.50 | 22.56 |
|
Gross Profit
|
0.11 | 15.30 |
|
Operating Expenses
|
15.20 | 130.73 |
|
Operating Profit (EBIT)
|
-15.09 | -115.43 |
|
Other Income
|
-- | -- |
|
Profit before Tax
|
-14.67 | -57.25 |
|
Provision for Tax
|
0.00 | -0.01 |
|
Profit after Tax (Net Income)
|
-14.67 | -57.25 |
|
Minority Interest
|
-- | -- |
|
Consolidated Profit
|
-17.26 | -- |
Liabilities ($ Mln)
| Organovo Holdings (ONVO) | 2seventy bio (TSVT) | |
|---|---|---|
|
Shareholder's Funds
|
3.60 | 210.81 |
|
Minority Interest
|
-- | -- |
|
Non-Current Liabilities
|
0.89 | 228.61 |
|
Current Liabilities
|
1.86 | 40.09 |
|
Total Liabilities
|
6.35 | 479.51 |
Assets ($ Mln)
| Organovo Holdings (ONVO) | 2seventy bio (TSVT) | |
|---|---|---|
|
Non-Current Assets
|
2.41 | 292.25 |
|
Current Assets
|
3.94 | 187.26 |
|
Total Assets
|
6.35 | 479.51 |
|
Total Debt*
|
1.39 | 243.72 |
|
Net Current Assets
|
2.08 | 147.16 |
Cashflow ($ Mln)
| Organovo Holdings (ONVO) | 2seventy bio (TSVT) | |
|---|---|---|
|
Cash From Operating Activities
|
-14.65 | -85.00 |
|
Cash Flow from Investing Activities
|
-0.97 | -- |
|
Cash from Financing Activities
|
1.44 | 0.42 |
|
Net Cash Inflow / Outflow
|
-- | -- |
Ratios
Profitability Ratios
| Organovo Holdings (ONVO) | 2seventy bio (TSVT) | |
|---|---|---|
|
ROCE (%)
|
-132.60 | -11.85 |
|
ROE (%)
|
-155.00 | -24.56 |
|
ROA (%)
|
-110.05 | -10.96 |
|
EBIT Margin (%)
|
-- | -- |
|
Net Margin (%)
|
-13,459.63 | -151.20 |
|
Cash Profit Margin (%)
|
-- | -- |
Growth Ratios
| Organovo Holdings (ONVO) | 2seventy bio (TSVT) | |
|---|---|---|
|
Revenue Growth (%)
|
-0.71 | -0.62 |
|
EBIT Growth (%)
|
-- | -- |
|
Net Profit Growth (%)
|
15.00 | 73.69 |
|
EPS Growth (%)
|
-- | 0.74 |
|
Book Value Growth (%)
|
-- | -- |
Valuation Ratios
| Organovo Holdings (ONVO) | 2seventy bio (TSVT) | |
|---|---|---|
|
Price / Earnings
|
-- | -2.69 |
|
Price / Book Value
|
-- | 0.73 |
|
Dividend Yield (%)
|
-- | -- |
|
EV/EBITDA
|
0.10 | -2.26 |
|
Market Cap ($ Cr)
|
-- | -- |
Solvency Ratios
| Organovo Holdings (ONVO) | 2seventy bio (TSVT) | |
|---|---|---|
|
Debt to Equity
|
0.39 | 1.16 |
|
Short term debt to equity ratio
|
0.14 | 0.08 |
|
Current Ratio
|
2.12 | 4.67 |
|
Quick Ratio
|
1.96 | 3.75 |
|
Interest Coverage
|
-37.73 | -25.45 |
Operating Efficiency Ratios
| Organovo Holdings (ONVO) | 2seventy bio (TSVT) | |
|---|---|---|
|
Debtors to sales (%)
|
30.28 | 20.55 |
|
Asset Turnover
|
0.01 | 0.07 |
|
Receivable days
|
309.96 | 102.22 |
|
Inventory Days
|
9.87 | 220.78 |
|
Payable days
|
31.82 | 57.33 |
|
Cash Conversion Cycle
|
288.00 | 265.67 |